Clinical trials
Phase 1 Breast Neoplasms trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 6 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 9 |
| The Netherlands Cancer Institute | 4 |
| AbbVie | 3 |
| Radboud University Medical Center | 2 |
| University Medical Center Groningen | 2 |
| AstraZeneca | 1 |
| Bayer | 1 |
| Eli Lilly and Company | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| G1 Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 34 |
| Neoplasms | 8 |
| Ovarian Neoplasms | 8 |
| Stomach Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Colonic Neoplasms | 4 |
| Endometrial Neoplasms | 4 |
| Lung Neoplasms | 3 |
| Carcinoma, Ductal, Breast | 2 |
| Colorectal Neoplasms | 2 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.